BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 30380447)

  • 1. Synthesis and anti-proliferative activity of some new quinoline based 4,5-dihydropyrazoles and their thiazole hybrids as EGFR inhibitors.
    George RF; Samir EM; Abdelhamed MN; Abdel-Aziz HA; Abbas SE
    Bioorg Chem; 2019 Mar; 83():186-197. PubMed ID: 30380447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
    Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
    Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives.
    Alkamaly OM; Altwaijry N; Sabour R; Harras MF
    Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000351. PubMed ID: 33252142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAF
    Mohassab AM; Hassan HA; Abdelhamid D; Gouda AM; Youssif BGM; Tateishi H; Fujita M; Otsuka M; Abdel-Aziz M
    Bioorg Chem; 2021 Jan; 106():104510. PubMed ID: 33279248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some 1,3,5-trisubstituted pyrazoline derivatives targeting breast cancer: Design, synthesis, cytotoxic activity, EGFR inhibition and molecular docking.
    George RF; Kandeel M; El-Ansary DY; El Kerdawy AM
    Bioorg Chem; 2020 Jun; 99():103780. PubMed ID: 32224337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
    Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
    Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
    Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
    Ibrahim DA; Abou El Ella DA; El-Motwally AM; Aly RM
    Eur J Med Chem; 2015 Sep; 102():115-31. PubMed ID: 26256032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
    Shaheen MA; El-Emam AA; El-Gohary NS
    Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study.
    Fakhry MM; Mattar AA; Alsulaimany M; Al-Olayan EM; Al-Rashood ST; Abdel-Aziz HA
    Molecules; 2023 Nov; 28(21):. PubMed ID: 37959874
    [No Abstract]   [Full Text] [Related]  

  • 11. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Zou M; Li J; Jin B; Wang M; Chen H; Zhang Z; Zhang C; Zhao Z; Zheng L
    Bioorg Chem; 2021 Sep; 114():105200. PubMed ID: 34375195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors.
    Abdelsalam EA; Zaghary WA; Amin KM; Abou Taleb NA; Mekawey AAI; Eldehna WM; Abdel-Aziz HA; Hammad SF
    Bioorg Chem; 2019 Aug; 89():102985. PubMed ID: 31121559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
    Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
    Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of 2-styrylquinolines as antitumour agents and EGFR kinase inhibitors: molecular docking study.
    El-Sayed MA; El-Husseiny WM; Abdel-Aziz NI; El-Azab AS; Abuelizz HA; Abdel-Aziz AA
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):199-209. PubMed ID: 29251017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a novel series of substituted quinolines acting as anticancer agents and selective EGFR blocker: Molecular docking study.
    Kumar CBP; Raghu MS; Prathibha BS; Prashanth MK; Kanthimathi G; Kumar KY; Parashuram L; Alharthi FA
    Bioorg Med Chem Lett; 2021 Jul; 44():128118. PubMed ID: 34015505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, antitumour and antioxidant activities of novel α,β-unsaturated ketones and related heterocyclic analogues: EGFR inhibition and molecular modelling study.
    El-Husseiny WM; El-Sayed MA; Abdel-Aziz NI; El-Azab AS; Ahmed ER; Abdel-Aziz AA
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):507-518. PubMed ID: 29455554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: Synthesis, anticancer, antimicrobial evaluation and computational studies.
    Othman IMM; Alamshany ZM; Tashkandi NY; Gad-Elkareem MAM; Anwar MM; Nossier ES
    Bioorg Chem; 2021 Sep; 114():105078. PubMed ID: 34161878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.